The approval of an Ebola drug is a big milestone in drug development. This week’s us food and Drug Administration approval is a huge milestone. The approval is part of our efforts to fight covid-19.

Before covid-19 spread across the world, Ebola was one of the most high-profile viral diseases on the planet.

A newsletter detailing the covid-19 research, developments, and stories that matter matter matter. A newsletter highlighting the covid-19 studies and developments that matter.

Remdesivir and zmapp did n’t dramatically reduce death rates in Ebola patients – at least not compared to their competitors. The other two had vastly better outcomes increasing survival rates among some patients to between 89 and 94 percent. One of the successful drugs, regn-eb3, later became inmazeb.

Clinical trials moved too slowly during the outbreak of Ebola in West Africa. The World Health Organization and others developed a framework that could be used to conduct clinical trials during future outbreaks.

The researchers put the plan into action when an outbreak started in the DRC in 2018. They faced particularly challenging circumstances, including distrust of government and health officials.

The success of the 2018 Ebola trial is part of what helped covid-19 research get going so quickly after the virus started spreading. Back in February, researchers had already started testing treatments, modeling their efforts off the Ebola trials in 2018.

We’re starting to see early signs of what drugs might work to treat covid-19. Even at remarkably fast speeds, it still took two years for the Ebola treatment to go from clinical trials to full FDA approval. Full approval may still be a distant speck on the horizon – even with all hands on deck.

A rare covid-19 complication was reported in children. Now, it’s showing up in adults, but it still seems rare.

The NIH paused Eli Lilly covid-19 antibody trial because of safety concerns. One of the two groups – either the placebo or the treatment – was doing better than the other.

It’s the second covid-19 vaccine trial to be put on hold. An unexplained illness in a participant caused the trial to pause.

Pfizer says it wo n’t seek vaccine authorization before mid-November. Pfizer promised that it would have results from its vaccine trials by mid to late October.

Remdesivir trial of remdesivir found that it did not prevent covid-19 deaths. The analysis has not been peer-reviewed yet, and some researchers say that the trial was not designed properly.

In the US, 50 states could mean 50 vaccine rollout strategies maryn McKenna takes us through the potentially messy rollout of a future covid-19 vaccine vaccine.

Mattie Kahn highlights four of the women who helped keep Elmhurst hospital running during New York City’s horrifying covid-19 spike.

More than 39,393,994 people worldwide have tested positive. May your road to recovery be smooth, may your way to recovery.